Objective; This extension study provided continued treatment to subjects with active rheumatoid arthritis who had participated for ≥16 weeks in a pharmacokinetic similarity study of PF‐05280586 (potential rituximab biosimilar). Objectives were to evaluate overall pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of PF‐05280586 after transition from a licensed rituximab product to PF‐05280586, and followup of biomarker and efficacy assessments. Methods; Subjects were offered ≤3 additional courses of treatment of PF‐05280586, with or without a single transition from rituximab EU (rituximab‐EU) or US (rituximab‐US) to PF‐05280586. Each course comprised 2 IV infusions (1,000 mg on Days 1 and 15, separated by 24 we...
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD...
As recommended in the current prescribing information, rituximab infusions in patients with rheumato...
Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (R...
ABP 798 is a proposed biosimilar to rituximab reference product (RP), an anti-CD20 monoclonal antibo...
Aims: Pharmacokinetic (PK) similarity was assessed among PF‐05280586 (a proposed biosimilar) vs. ri...
Wide usage of biologic disease-modifying anti-rheumatic drugs (DMARDs) biosimilars in clinical pract...
Steadily growing knowledge about pathogenetic mechanisms in autoimmune rheumatic diseases (RDs) has ...
There is evidence supporting that there are no relevant clinical differences between dosing rituxi...
Background/objectives: ABP 798 is a proposed biosimilar to the originator biologic rituximab, an ant...
B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chim...
Study I – Biological disease-modifying anti-rheumatic drugs (DMARDs) and the risk of gastrointestina...
Background: Rituximab (RTX) in combination with methotrexate (MTX) has been licensed since 2006 for ...
INTRODUCTION: Patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor(anti...
Rheumatoid arthritis is a chronic, disabling condition and the most common form of inflammatory arth...
OBJECTIVE: To characterize the real-world effectiveness of rituximab (RTX) in patients with rheumato...
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD...
As recommended in the current prescribing information, rituximab infusions in patients with rheumato...
Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (R...
ABP 798 is a proposed biosimilar to rituximab reference product (RP), an anti-CD20 monoclonal antibo...
Aims: Pharmacokinetic (PK) similarity was assessed among PF‐05280586 (a proposed biosimilar) vs. ri...
Wide usage of biologic disease-modifying anti-rheumatic drugs (DMARDs) biosimilars in clinical pract...
Steadily growing knowledge about pathogenetic mechanisms in autoimmune rheumatic diseases (RDs) has ...
There is evidence supporting that there are no relevant clinical differences between dosing rituxi...
Background/objectives: ABP 798 is a proposed biosimilar to the originator biologic rituximab, an ant...
B cells play an important role in the pathogenesis of rheumatoid arthritis (RA). Rituximab is a chim...
Study I – Biological disease-modifying anti-rheumatic drugs (DMARDs) and the risk of gastrointestina...
Background: Rituximab (RTX) in combination with methotrexate (MTX) has been licensed since 2006 for ...
INTRODUCTION: Patients with active rheumatoid arthritis (RA) despite anti-tumor necrosis factor(anti...
Rheumatoid arthritis is a chronic, disabling condition and the most common form of inflammatory arth...
OBJECTIVE: To characterize the real-world effectiveness of rituximab (RTX) in patients with rheumato...
The Russian biotechnological company «BIOCAD» has designed a chimeric monoclonal antibody against CD...
As recommended in the current prescribing information, rituximab infusions in patients with rheumato...
Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (R...